It decreases the tumorigenesis marker such as matrix metallopeptidase 3 (MMP-3), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and proliferating cell nuclear antigen (PCNS), and stem cell markers including CD133 leading to reducing tumor size of REM134 canine mammary carcinoma [142]. This evidence concerns the gene IL6 and neoplasm.